New Study Suggests J Recipients Should Be Boosted To Protect Against Delta Variant

Recipients of the Johnson & Johnson single-injection COVID-19 vaccine may need a second dose to protect against the Delta and Lambda coronavirus variants because it is less effective against them, a new study suggests, by The New York Times.

“The message we wanted to get across was not that people shouldn’t get the J&J vaccine, but we hope that in the future it will be boosted with a dose of J&J or a booster with [the Pfizer and Moderna COVID-19 vaccines]”said Nathaniel Landau, a virologist at the Grossman School of Medicine at New York University who led the study. Time.

The study, which was not peer-reviewed, involved Landau and his team in examining blood samples taken from 17 people who had received two doses of the Pfizer and Moderna vaccines and 10 people with one dose of J&J . The J&J vaccine started with a lower efficacy rate, which fell more sharply against the variants, the Time reports. However, since the study was based on lab experiments, the Food and Drug Administration is unlikely to change its single-dose recommendation because of this, the Time Remarks. In addition, separate small studies published by researchers affiliated with J&J found that the vaccine’s protection increased over time. Read more on The New York Times.

You may also like

Melania Trump reportedly tried 4 times to block election night at the White House

IRS Enforcement No Longer On Table As Funding Bipartite Infrastructure Agreement, Says GOP Senator

Weapons of mass destruction